Colgate-Palmolive stock gains analyst backing as RBC keeps $104 target

Published on 09/08/2026 at 22:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Colgate-Palmolive stock trades near the mid-point of its 52-week range while RBC Capital and other analysts reiterate upbeat ratings and double-digit upside targets, keeping the consumer staples name in focus for defensive investors.

Moderne Konsumgüter-Fabrikanlage mit Fließband für Körperpflegeprodukte — Colgate-Palmolive Konsumgüterproduktion US1941621039 zeigt sterile Zahnpastatube-Abfüllanlage auf modernem industriellen Fließband mit Arbeitern, Illustration mit AI erstellt.

Colgate-Palmolive stock (ISIN US1941621039) is trading around USD 88 per share as of September 8, 2026, with analysts led by RBC Capital reaffirming an Outperform rating and a USD 104.00 price target that implies roughly 13 percent upside from current levels.

Analysts see upside from current valuation

According to Investing.com, Colgate-Palmolive Company (NYSE:CL) recently traded at about USD 88.18, while RBC Capital reiterated its Outperform stance and maintained a USD 104.00 target, suggesting around 13 percent potential upside based on this price snapshot as of September 8, 2026.

Data compiled by MarketBeat show a consensus price target of USD 99.00 for Colgate-Palmolive, representing roughly 12.0 percent upside from a current price quoted near USD 88.37, and an average analyst rating described as Moderate Buy with 19 analysts covering the stock.

Valuation metrics and fundamentals

MarketBeat’s overview indicates that Colgate-Palmolive’s market capitalization stands at approximately USD 70.53 billion, with a trailing price-to-earnings ratio of 35.09 and a dividend yield of about 2.40 percent as of September 8, 2026, placing the stock among higher-valued defensive consumer names but with a steady income component.

Further valuation analysis from GuruFocus points to a GF Value of roughly USD 95.23 for Colgate-Palmolive versus a current price cited around USD 88.77, implying the shares are between about 6.8 percent and 7.5 percent undervalued depending on the intraday quote used on September 8, 2026.

GuruFocus also notes that Colgate-Palmolive’s current P/E multiple of about 35.23 times compares to a 5-year median P/E of 31.26 times, suggesting that while the stock trades at a premium to its own historical valuation, it may still offer modest upside relative to intrinsic value estimates when combined with its dividend and earnings profile.

Strategic context and regional performance

Beyond headline valuation, analysts such as RBC and UBS highlight Colgate-Palmolive’s long-term strategy aimed at sustaining organic growth to 2030 through disciplined capital allocation and reinforcing its global leadership in oral care, with particular strength in Latin America where the company holds over 50 percent market share in some categories according to Investing.com.

Commentary cited by Finimize emphasizes that RBC expects Colgate-Palmolive’s US toothpaste business to stabilize by the first quarter of 2027, a timeline that matters for investors because the United States remains large enough to influence the group’s overall growth mix and sentiment around the stock.

Representative product: Colgate toothpaste franchise

Colgate-Palmolive’s most visible product line for many consumers is its Colgate-branded toothpaste, which anchors the company’s global oral care portfolio and underpins its high market shares in regions like Latin America and significant presence in North America, providing recurring revenue that supports the valuation metrics and analyst confidence described above.

Stock level within the 52-week range

As of September 8, 2026, MarketBeat data show Colgate-Palmolive stock trading around USD 88.48, against a 52-week low of USD 74.54 and a 52-week high of USD 99.33, meaning the shares currently sit closer to the middle of their one-year trading range while analysts’ average target of USD 99.00 points toward a potential move back near the top of that corridor.